% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nieder:299514,
      author       = {C. Nieder and I. Popp and A.-L. Grosu$^*$},
      title        = {{E}xternal {V}alidation of an {E}xtended {P}rognostic
                      {A}ssessment {M}odel in {P}atients {W}ith {B}rain
                      {M}etastases from {S}mall-cell {L}ung {C}ancer.},
      journal      = {Cancer diagnosis $\&$ prognosis},
      volume       = {5},
      number       = {2},
      issn         = {2732-7787},
      address      = {Kapandriti, Attiki, Greece},
      publisher    = {International Institute of Anticancer Research},
      reportid     = {DKFZ-2025-00472},
      pages        = {171-178},
      year         = {2025},
      abstract     = {Recently, the small-cell lung cancer (SCLC) grade model for
                      patients with brain metastases was developed by a Japanese
                      group. It includes sex, performance status, number of brain
                      metastases, primary tumor control and presence of
                      extracranial metastases. The aim of the present study was to
                      validate this prognostic score in a European cohort of
                      patients.The retrospective validation study included 189
                      patients from two centers in Germany and Norway. Survival
                      according to the SCLC grade score was evaluated. Additional
                      prognostic factors were analyzed.Median survival was 7.5
                      months. The 3-tiered SCLC grade score based on the sum of
                      adverse prognostic features was significantly associated
                      with survival (p<0.001): A higher point sum resulted in
                      shorter survival. However, in our validation cohort, age
                      affected survival to the same degree as several parameters
                      that were part of the score.This validation study supports
                      the international applicability of the SCLC grade model.
                      Age, which has also been identified as a relevant prognostic
                      factor in other previous studies (including the SCLC Graded
                      Prognostic Assessment), may deserve consideration when
                      trying to optimize survival prediction. Given that different
                      studies identified different age limits, e.g., 70 or 75
                      years, merged databases are needed to provide definitive
                      conclusions.},
      keywords     = {Radiation therapy (Other) / brain metastases (Other) /
                      prognostic factors (Other) / small cell lung cancer (Other)
                      / stereotactic radiotherapy (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40034954},
      pmc          = {pmc:PMC11871855},
      doi          = {DOI:10.21873/cdp.10427},
      url          = {https://inrepo02.dkfz.de/record/299514},
}